GVHD,Acute Clinical Trial
Official title:
A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease
The objective of this clinical study is to demonstrate safety and feasibility of single-dose infusion of Ossium MSCs product (OSSM-001) to treat steroid refractory acute GVHD (SR-aGVHD).
The dose escalation will be used to establish a maximum tolerated dose, starting from 2M cells/kg. If no safety issues are seen, then MSCs dose maybe escalated to 6M cells/kg, 12M cells/kg and 24M cell/kg based on data review from each cohort. Additional studies will be conducted to establish a dosing regimen and to evaluate the safety and efficacy of OSSM-001 for SR-aGVHD patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
| Active, not recruiting |
NCT04522843 -
Analysis of Intestinal Defensin Expression in Acute GVHD
|
||
| Recruiting |
NCT05718791 -
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
|
||
| Recruiting |
NCT05368181 -
MAP-guided Preemptive Therapy of aGvHD
|
Phase 2 | |
| Recruiting |
NCT05401955 -
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
|
N/A | |
| Not yet recruiting |
NCT06315309 -
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT04220632 -
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04284904 -
Role of aGVHD Biomarkers on aGVHD Risks
|
||
| Not yet recruiting |
NCT06164288 -
Safety and Efficacy Study of hAESCs Therapy for aGVHD
|
Phase 1 | |
| Recruiting |
NCT06462365 -
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
|
Phase 1 |